Supplement 2. Sensitivity analysis of C19-YRSm Symptom Severity from baseline to week 12.

Multiple imputation for missing data

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Mean Change from Baseline (95% CI)** | | **Between-Group Difference (raw)** | |
| **Cs4 group**  **(n = 55)** | **Waitlist control group**  **(n=60)** | **Cs4 group vs.**  **Control group** | **P Value** |
| C19-YRSm Symptom Severity |  |  |  |  |
| Week 12 | -10.0 (-12.4 to -7.6) | -0.7 (-3.4 to 2.1) | -9.3 (-12.9 to -5.7) | <0.001 |

Inverse-Probability weighting for missing data

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Mean Change from Baseline (95% CI)** | | **Between-Group Difference (raw)** | |
| **Cs4 group**  **(n = 55)** | **Waitlist control group**  **(n=60)** | **Cs4 group vs.**  **Control group** | **P Value** |
| C19-YRSm Symptom Severity |  |  |  |  |
| Week 12 | -10.0 (-12.4 to -7.6) | -0.7 (-3.4 to 2.1) | -9.9 (-14.0 to -5.8) | <0.001 |

Sensitivity analysis of C19-YRSm Symptom Severity from baseline to week 12.

|  |  |  |
| --- | --- | --- |
| **Variables** | **Between-Group Difference** | |
| **Cs4 group vs.**  **Control group** | **P Value** |
| Generalized regression model | -9.4 (-13.1 to -5.8) | <0.001 |
| Generalized regression model adjusted for doses of vaccine | -9.9 (-13.7 to -6.2) | <0.001 |
| Generalized regression model adjusted for duration | -8.7 (-12.7 to -4.8) | <0.001 |
| Multiple imputation | -9.3 (-12.9 to -5.7) | <0.001 |
| Inverse-Probability weighting | -9.9 (-14.0 to -5.8) | <0.001 |